William Blair Has Optimistic Outlook of ADPT FY2025 Earnings

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) – Investment analysts at William Blair upped their FY2025 earnings estimates for Adaptive Biotechnologies in a research note issued to investors on Wednesday, November 5th. William Blair analyst A. Brackmann now forecasts that the company will earn ($0.49) per share for the year, up from their previous forecast of ($0.56). The consensus estimate for Adaptive Biotechnologies’ current full-year earnings is ($0.92) per share. William Blair also issued estimates for Adaptive Biotechnologies’ Q4 2025 earnings at ($0.18) EPS, Q1 2026 earnings at ($0.18) EPS, Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.14) EPS, Q4 2026 earnings at ($0.12) EPS and FY2026 earnings at ($0.60) EPS.

Other equities research analysts have also recently issued research reports about the company. JPMorgan Chase & Co. boosted their price objective on Adaptive Biotechnologies from $17.00 to $20.00 and gave the company an “overweight” rating in a research note on Thursday, November 6th. TD Cowen upped their price target on shares of Adaptive Biotechnologies from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Wednesday, August 6th. Guggenheim initiated coverage on shares of Adaptive Biotechnologies in a research report on Tuesday, September 30th. They set a “buy” rating and a $20.00 price objective on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Wednesday, October 8th. Finally, Wall Street Zen upgraded shares of Adaptive Biotechnologies from a “hold” rating to a “buy” rating in a research note on Saturday. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.56.

Adaptive Biotechnologies Stock Down 1.2%

NASDAQ:ADPT opened at $14.53 on Monday. The stock’s 50 day moving average price is $14.93 and its 200 day moving average price is $12.21. The company has a market capitalization of $2.22 billion, a PE ratio of -17.72 and a beta of 2.09. Adaptive Biotechnologies has a 52-week low of $4.27 and a 52-week high of $17.89.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its earnings results on Wednesday, November 5th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.01. Adaptive Biotechnologies had a negative return on equity of 60.93% and a negative net margin of 59.07%.The business had revenue of $93.97 million for the quarter, compared to analysts’ expectations of $58.76 million. During the same quarter in the previous year, the firm earned ($0.22) earnings per share. The business’s revenue was up 102.4% compared to the same quarter last year.

Institutional Investors Weigh In On Adaptive Biotechnologies

A number of institutional investors have recently added to or reduced their stakes in ADPT. Vanguard Group Inc. raised its stake in shares of Adaptive Biotechnologies by 4.0% during the 1st quarter. Vanguard Group Inc. now owns 11,143,428 shares of the company’s stock worth $82,796,000 after buying an additional 428,540 shares in the last quarter. Ameriprise Financial Inc. grew its holdings in Adaptive Biotechnologies by 801.6% during the first quarter. Ameriprise Financial Inc. now owns 6,642,476 shares of the company’s stock worth $49,355,000 after acquiring an additional 5,905,756 shares during the period. Braidwell LP acquired a new position in Adaptive Biotechnologies during the first quarter worth $35,692,000. Geode Capital Management LLC raised its position in Adaptive Biotechnologies by 15.6% in the second quarter. Geode Capital Management LLC now owns 3,215,171 shares of the company’s stock worth $37,461,000 after acquiring an additional 434,347 shares in the last quarter. Finally, Driehaus Capital Management LLC lifted its holdings in Adaptive Biotechnologies by 154.4% in the first quarter. Driehaus Capital Management LLC now owns 2,152,335 shares of the company’s stock valued at $15,992,000 after acquiring an additional 1,306,164 shares during the period. Hedge funds and other institutional investors own 99.17% of the company’s stock.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.